CIMB Securities cuts Amway's earnings forecasts by up to 13.2pct

KUALA LUMPUR: CIMB Securities Sdn Bhd has cut its core net profit forecasts for Amway (Malaysia) Holdings Bhd by up to 13.2 per cent following weaker-than-expected third-quarter results.
Analyst Walter Aw Lik Hsin lowered the earnings forecasts by 13.2 per cent for financial year 2026 (FY26), 10.3 per cent for FY27 and 4.5 per cent for FY28, reflecting weaker sales assumptions and continued pressure from operating expenses.
He also reduced the target price to RM3.35 from RM4.05, while maintaining his "Reduce" recommendation on the stock.
Amway's core net profit (CNP) for the third quarter ended Sept 30, 2026, fell 38 per cent year-on-year (YoY) to RM11.8 million, although it recovered 92.1 per cent quarter-on-quarter (QoQ).
This brought its nine-month FY26 CNP to RM27.8 million, down 17.6 per cent YoY, accounting for 63.1 per cent of CIMB Securities' full-year forecast and 77.3 per cent of Bloomberg consensus estimates.
Aw said the results were below expectations as sales underperformed the firm's projections, with revenue declining 6.3 per cent YoY and 4.9 per cent QoQ to RM258.3 million.
The weaker revenue reflected a higher comparative base from the launch of cellular health products in September last year and promotional campaigns in May and June this year.
Despite softer sales, gross profit margin expanded 4.3 percentage points YoY to 27 per cent, supported by product price adjustments.
However, the improvement was offset by a 33.7 per cent increase in selling and administrative expenses to RM41.3 million, driven by higher selling and marketing costs.
A higher effective tax rate of 25.4 per cent also weighed on earnings.
Aw expects Amway's operating environment to remain challenging in Q4 FY26 as consumers continue prioritising essential spending amid pressure on discretionary expenditure.
"While recent product price adjustments have aided margin recovery, we expect sales to remain weak owing to softer sales volumes and the absence of new flagship products acting as a catalyst," he said.
Amway is also focusing on expanding its health and wellbeing portfolio, particularly in healthy ageing products, supported by investments in sales capabilities and product innovation.
However, Aw expects these initiatives to take time to generate meaningful sales growth.
He also cautioned that higher selling prices could further weigh on demand, limiting the benefits of recent price adjustments.
"We expect profitability to remain flat QoQ in Q4 FY26, supported by recent pricing adjustments across all its product offerings, while a sustained earnings recovery hinges on stronger consumer demand," he added.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.